Oxford’s COVID-19 vaccine creates an immune response in the elderly

Bangalore / London (ANTARA) – Candidates for the COVID-19 vaccine made by the University of Oxford and AstraZeneca Plc are capable of producing immunity, as demonstrated by the results of clinical trials involving a number of elderly people – the group considered most vulnerable to COVID-19, said two sources as quoted by Financial Times (FT).

According to the source, the vaccine candidate could trigger an immune response from antibodies and T cells in the elderly. The findings, they said, are an impetus for researchers who want to prove that vaccines can prevent elderly people from experiencing severe illness and even dying from COVID-19.

FT reported that the results of the study would soon be published by the researchers, but the media did not mention the name of the journal.

Also read: Argentina and Mexico agree to produce AstraZeneca’s COVID-19 vaccine

Also read: Indonesian students participate in researching the COVID-19 vaccine at Oxford, UK

The findings reinforce data published by researchers in July 2020. The data suggest a vaccine candidate made by the University of Oxford and AstraZeneca can trigger a “strong immune response” in the bodies of adults aged 18 to 55, the FT reports. Some people, as reported by FT, got the data from blood immunogenicity tests.

However, a positive result from an immunogenicity test does not guarantee that the vaccine candidate is safe and effective for use by the public, especially those who are elderly.

Candidates for the COVID-19 vaccine made by AstraZeneca and the University of Oxford are among the foremost candidates for the SARS-CoV-2 anti-virus in an effort to prevent the transmission of COVID-19.

The University of Oxford and AstraZeneca have not yet answered questions on the matter.

One of the COVID-19 vaccine candidates, called AZD1222 or ChAdOx1 nCoV-19, was made by researchers from the University of Oxford and the license was submitted in April 2020 to AstraZeneca Plc.

AstraZeneca is in charge of running clinical trials and vaccine production.

The pharmaceutical company on Friday said it was resuming clinical trials of AZD1222 in the United States after local authorities issued a permit for the activity.

AZD1222 is prepared from an attenuated flu virus and samples were taken from chimpanzees. The vaccine is designed to provoke the body to create an immune response when attacked by COVID-19.

Source: Reuters

Also read: T-cell test for COVID-19 vaccine, UK collaborating with Oxford company

Also read: EU regulators begin reviewing AstraZeneca-made COVID-19 vaccine

Translator: Genta Tenri Mawangi
Editor: Mulyo Sunyoto

Share on facebook
Share on pinterest
Share on twitter
Share on linkedin
Share on email


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.